PepGen: Stock Slides On FDA Study Hold - I'm Firmly On The Sidelines [Seeking Alpha]
PepGen Inc. (PEPG)
Company Research
Source: Seeking Alpha
PGN-EDODM1 leverages proprietary EDO technology to target myotonic dystrophy type 1 (DM1) by restoring normal splicing function of MBNL1. Phase 1 data showed dose-dependent, best-in-class splicing correction and robust muscle tissue concentration after a single dose, but the real tests of its candidate lie ahead. DM1 is a severe, progressive neuromuscular disorder with significant unmet need; PEPG's lead candidate addresses a large global patient population. PepGen has a long road to travel towards a potential approval shot in DM1, however, and this setback is unwelcome. I cannot make the bull case for PEPG stock based on my due diligence. Looking for more investing ideas like this one? Get them exclusively at Haggerston BioHealth. Learn More » J Studios/DigitalVision via Getty Images Investment Overview The stock of PepGen Inc. ( PEPG ) is down 20% in early trading today, after the company released its Q4 and full-year 2025 earnings, and shared the news that More on
Show less
Read more
Impact Snapshot
Event Time:
PEPG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PEPG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PEPG alerts
High impacting PepGen Inc. news events
Weekly update
A roundup of the hottest topics
PEPG
News
- PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire
- PepGen muscular dystrophy drug gets ‘surprise' hold from FDA [Yahoo! Finance]Yahoo! Finance
- PepGen GAAP EPS of -$0.27 beats by $0.12 [Seeking Alpha]Seeking Alpha
- US FDA puts partial clinical hold on PepGen's muscle disease drug trial [Yahoo! Finance]Yahoo! Finance
- PepGen Announces Regulatory Updates on FREEDOM2 [Yahoo! Finance]Yahoo! Finance
PEPG
Earnings
- 3/4/26 - Beat
PEPG
Sec Filings
- 3/4/26 - Form 8-K
- 3/4/26 - Form S-8
- 3/4/26 - Form 10-K
- PEPG's page on the SEC website